In a recent statement the MHRA has clarified how the UK’s clinical trials rules will function in partnership with the EU after Britain leaves March next year. “As part of exit negotiations, MHRA is working to ensure that we continue to have the best possible environment in which to support clinical trials,” the agency said.
Many people are aware of Bitcoin and other cryptocurrencies but are unaware, perhaps, of how and why they were and are being developed. Cryptocurrencies all rely on the use of decentralised ledger technology, or blockchain, thus avoiding the necessity for a “middle man” or central authority to regulate the value and flow of currency, such
Clinical Professionals will be attending the City & Financial Global’s ‘BREXIT: What does it mean for the Life Sciences’ Summit, which takes place in London on 20th June. The event will examine both short-term and long-term strategies for navigating BREXIT safely and allowing the UK to keep its current status as a leading Life Sciences
What is the new GDPR and how will it affect the Clinical Research Sector? The new General Data Protection Regulation (No. 2016/679, or ‘GDPR’) came into force on 25 May 2018 across all EU countries including the UK. The new Regulation aims to provide a high level of protection for personal data, to ensure that
Recent study data by the FDA has found that older blood cancer patients (75+) are severely under-represented in clinical trials
Results from the FDA’s first comprehensive examination of clinical trial enrolment in older patients with blood cancers has revealed that patients over 75 are significantly underrepresented. When looking at the occurrence of these conditions, it has recently been found that one in five patients in the US who are diagnosed with blood cancer are over
An experimental therapy for bladder cancer is predicted to soon be entering Phase I clinical trials in the UK following a development pact signed between Cancer Research UK, its commercial arm Cancer Research Technology, and Sitka Biopharma, a Canadian biotech. Sitka’s therapy (STK-01) is being developed to improve delivery of chemotherapy in non-muscle invasive bladder